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I. INTRODUCTION 
Historically, prescriptive authority has been reserved for physicians.1  
However, in light of the heightened responsibilities of health care providers, 
prescriptive authority has been expanded to include other groups such as 
nurses and physician’s assistants.2  Pharmacists are the next group seeking 
the right to prescribe medication through collaboration with other health care 
providers.3  Most states provide some form of prescriptive authority to 
pharmacists, though the specific authority varies from state to state.4 
The expansion of the pharmacist’s role is not completely novel.  The 
pharmacist’s role expanded as early as the 1960s, when “[h]ospital 
pharmacists consulted with physicians about appropriate drug therapy and 
 
 1   Phyllis Coleman & Ronald A. Shellow, Extending Physician’s Standard of Care to 
Non-Physician Prescribers: The Rx For Protecting Patients, 35 IDAHO L. REV. 37, 46 (1998). 
 2   Id. at 45. 
 3   CENTERS FOR DISEASE CONTROL AND PREVENTION, ADVANCING TEAM-BASED CARE 
THROUGH COLLABORATIVE PRACTICE AGREEMENTS: A RESOURCE AND IMPLEMENTATION 
GUIDE FOR ADDING PHARMACISTS TO THE CARE TEAM 8 (2017).  
 4   Id. 
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participating in initial prescription decisions.”5  Washington State pioneered 
expanding prescribing rights to pharmacists in 1979, when the state passed a 
law permitting pharmacists to prescribe under specific protocols with 
physician supervision.6  Many states soon followed suit, imposing their own 
various limitations such as additional training, restrictions, and heightened 
physician supervision.”7  Although it was the first state to enact pharmacist 
prescribing legislation, Washington has made few changes to its law since 
then.  Washington allows for broad “collaborative practice agreements,” 
allowing limited prescriptive authority to pharmacists with physician 
supervision.8  In California, the state Business & Professions Code describes 
a new type of pharmacist license—the advanced practice pharmacist 
license—which grants prescriptive authority to licensed pharmacists with 
additional training under certain conditions.9  In this comment, I will 
examine the background of the legislative and regulatory frameworks 
governing prescriptive authority, as well as the underlying policies that these 
laws seek to promulgate.  I will then compare the legislation in both 
Washington and California, arguing that there is a place for pharmacist 
prescribers, but that the legislation is overbroad and must be constricted to 
avoid unintended and potentially harmful consequences. 
The health care community can avoid the aforementioned harmful 
consequences by eliminating broad and vague delegations of power from a 
physician to a pharmacist and increasing the legislation surrounding 
pharmacist prescribing.  Pharmacists should be required to receive further 
advanced training in order to prescribe.  However, this right to prescribe 
should not be extended to include the right to diagnose, and states and 
medical boards must legislate carefully in order to avoid this confusion of 
duties.  Finally, there must be more physician oversight over pharmacists 
exercising their right to prescribe, including communication and review 
requirements. 
II. BACKGROUND 
For many years, there has been tension in the health care provider 
community over which groups should be granted the right to prescribe.10  
Many physicians believe that only a trained physician should have the right 
to prescribe medication to a patient.11  Physicians undergo extensive training 
 
 5   Coleman, supra note 1, at 65. 
 6   Coleman, supra note 1, at 65. 
 7   Coleman, supra note 1, at 65. 
 8   WASH. ADMIN. CODE § 246-863-100 (2018). 
 9   CAL. BUS. & PROF. CODE § 4052.6 (2018). 
 10   Coleman, supra note 1, at 58. 
 11   See, e.g., Anna Gorman, Pharmacists Increasingly Take On Clinical Roles, KAISER 
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on diagnosis and patient care, and many believe they are best positioned to 
decide what medication will help a sick patient.12  As a result of their training, 
physicians are granted unrestricted prescriptive authority in all fifty states.13  
Two groups of secondary providers—nurses and physician’s assistants—
began seeking expansion of their scope of practice around 1965.14  These 
providers argue that they are able to diagnose and treat patients with 
medication due to their extensive training.15  Secondary providers argue that 
they provide the same quality of care as physicians, but at a lesser cost and 
higher patient satisfaction.16  They also believe that allowing secondary 
providers to have prescribing rights will improve health care access in 
underserved populations.17  These groups believe the objections coming 
from physicians are not based on concerns for patients but are rather 
manifestations of a  “turf war” between physicians and other health care 
providers.18 
Despite objections from physicians, legislators responded to these 
requests by amending state laws to include diagnosing and prescribing in the 
list of duties of nurse practitioners and physician’s assistants.19  As it 
currently stands, all fifty states provide nurses and physician’s assistants with 
prescriptive authority in some capacity.20  Some states limit prescriptions of 
controlled substances, while others require direct supervision by a 
physician.21 
Many physicians have pushed back at the expansion of prescribing 
rights to these secondary health care providers.22  Physicians argue that there 
 
HEALTH NEWS (Feb. 11, 2014), https://khn.org/news/pharmacists-see-clinical-role-expand/; 
Katy Grimes, Doctors Rip Idea of Nurses Playing Doctor, CALWATCHDOG, (Aug. 8, 2013), 
https://calwatchdog.com/2013/08/08/doctors-rip-idea-of-nurses-playing-doctor/. 
 12   Coleman, supra note 1, at 52. 
 13   Coleman, supra note 1, at 46. 
 14   Coleman, supra note 1, at 59. 
 15   Coleman, supra note 1, at 48. 
 16   Coleman, supra note 1, at 48. 
 17   Coleman, supra note 1, at 48. 
 18   Coleman, supra note 1, at 48. There is little evidence to back up either group of 
secondary practitioner’s claims, as they are often opinions or inferences. For example, some 
secondary provider believe that physicians are “reacting to rising health care costs and 
severely restricted third-party payor reimbursement by attempting to protect tasks 
traditionally within their exclusive domain,” such as prescribing. But physicians hold that 
these other providers lack the education and training necessary to safely prescribe. In fact, 
physicians contend a primary reason these secondary providers are seeking prescribing 
authority is to increase their income. Coleman, supra note 1, at 58. 
 19   Coleman, supra note 1, at 59. 
 20   Mary Beck, Improving America’s Health Care: Authorizing Independent Prescriptive 
Privileges for Advanced Practice Nurses, 29 U.S.F. L. REV. 951, 954 (1995). 
 21   Id. 
 22   See Gorman, supra note 11 (“some physicians, however, are wary of pharmacists 
doing too much on their own.”). 
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is not enough collaboration and communication between secondary 
providers and physicians.23  As a result of the lack of communication, 
important information can slip through the cracks.  Additionally, they 
believe these groups do not receive enough training in diagnosing and 
prescribing.24  Physician’s assistants and nurses are generally required to 
receive more training before they can prescribe; in light of this training, they 
are typically deemed competent to diagnose basic and obvious diseases and 
conditions and treat accordingly.25  However, more complicated, nuanced, or 
atypical ailments can cause concerns.  Often, symptoms of a harmful disease 
may mimic those of a more mild ailment.26 Diagnosis and subsequent 
prescribing is further complicated in instances where several ailments co-
exist.27  In these cases, the absence of a comprehensive medical background 
increases the probability that patients will be misdiagnosed.28  Because of 
this, a non-physician prescriber may not know to refer a patient with a serious 
disease if the provider believes it to be a basic ailment.29  There is also a 
standard of care issue when non-physicians prescribe.  Physicians believe 
that if nurses and physician’s assistants retain the right to prescribe, they 
should be held to the same standard in malpractice actions as a physician, 
but nurses and physician’s assistants would prefer to be held to a lower 
standard.30 
Pharmacists face many of the same challenges and objections to nurses 
and physician’s assistants prescribing, but nevertheless they became the next 
group of health care providers to receive the coveted right to prescribe.31  
Most states allow pharmacists some form of limited prescriptive authority.32  
These states typically require a collaborative practice agreement or similar 
arrangement with a practicing physician.33  A collaborative practice 
agreement (“CPA”) is an agreement between a physician and a pharmacist, 
nurse, or other health care provider that delegates some form of authority 
from the physician to the aforementioned provider.34  These agreements can 
go by other names as well, such as protocols, standing orders, collaborative 
 
 23   Gorman, supra note 11. 
 24   See Coleman, supra note 1, at 50. 
 25   Coleman, supra note 1, at 49–50. 
 26   Coleman, supra note 1, at 50. 
 27   Coleman, supra note 1, at 50. 
 28   Coleman, supra note 1, at 50. 
 29   Coleman, supra note 1, at 50. 
 30   Coleman, supra note 1, at 78–79. 
 31   See Gorman, supra note 11. 
 32   CENTERS FOR DISEASE CONTROL AND PREVENTION, supra note 3, at 8. 
 33   Collaborative Practice Agreements: Resources and More, NAT’L ALL. OF STATE 
PHARMACY ASS’NS., www.naspa.us/cpa (last visited Feb. 2, 2020). 
 34   Id. 
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care agreements, and others.35  A CPA is just one of several pathways by 
which a pharmacist may gain prescriptive authority.36  A physician can 
choose whether to enter into a CPA with a pharmacist and may delegate 
some form of authority to the pharmacist.37  This authority can include the 
initiation of medication, otherwise known as prescribing, as well as 
modification or discontinuation of medication.38  Other possibilities include 
the authority to substitute another drug in the same drug class for the 
medication originally prescribed.39 
Moreover, the agreement may be limited in setting or may contain a 
requirement that the pharmacist prescribing a drug notifies the treating 
physician within a certain time frame after doing so.40  The full range of 
pharmacist prescriptive powers allowed by CPAs varies from state to state 
and agreement to agreement.41  Some states only allow modification of 
medication, but not initiation of a new drug therapy.42  Some states 
specifically limit the classes of drugs that pharmacists may prescribe, while 
others remain silent on class restrictions.43  Some of the most common 
medications that are allowed to be prescribed are those that treat asthma, 
hypertension, hyperlipidemia, and COPD.44  Although these are typical 
examples of permitted pharmacist-prescribed medication, many states have 
no explicit restrictions on drug classes that a pharmacist may prescribe.45 
The pharmacist prescribing laws of Washington and California 
represent two different eras of prescriptive law history.  Washington’s statute 
is vague, broad, and without a recent update.46  It is a representation of an era 
 
 35   CENTERS FOR DISEASE CONTROL AND PREVENTION, supra note 3, at 8. 
 36   Pharmacist Prescribing: Statewide Protocols and More, NAT’L ALL. OF STATE 
PHARMACY ASS’NS., www.naspa.us/swp (last visited Feb. 2, 2020). 
 37   Collaborative Practice Agreements: Resources and More, supra note 33. 
 38   See, e.g., WASH. ADMIN. CODE § 246-863-100 (2)(c). 
 39   See N.D. ADMIN. CODE § 61-04-08-06(2) (2018). 
 40   Compare TEX. OCC. CODE § 157.101(b-1)(2) (2018) (limiting delegation authority to 
hospitals, hospital-based clinics, and academic health care institutions), with WASH. ADMIN. 
CODE § 246-863-100 (specifying no time limit in setting). See CAL. BUS. & PROF. CODE § 
4052.2 (2018) (requiring notice within twenty-four hours). 
 41   See Pharmacist Prescribing: Statewide Protocols and More, supra note 36. 
 42   N.J. STAT. ANN. § 45:14-41 (2018) (allowing only for modification or discontinuation 
of drug therapy by a pharmacist). 
 43   Compare 243 MASS. CODE REGS. § 2.12(4)(e)(6)(b) (2018) (limiting the types of 
drugs that may be prescribed in community settings and disallowing controlled substance 
prescriptions), with WASH. ADMIN. CODE § 246-863-100 (no language to restrict the classes 
of drugs pharmacists may prescribe). 
 44   243 MASS. CODE REGS. § 2.12(4)(e)(6)(b). 
 45   See, e.g., WASH. ADMIN. CODE § 246-863-100 (no language to restrict the classes of 
drugs pharmacists may prescribe); KY. REV. STAT. §§315.010 (no language regarding classes 
of drugs a pharmacist may prescribe). 
 46   WASH. ADMIN. CODE § 246-863-100 (no agency filings affecting this section since 
2003). 
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when pharmacist prescribing law was murky and actual pharmacist 
prescribers were uncommon.  The law has remained unchanged despite the 
widening landscape of prescriptive authority and the expansion of the role of 
the pharmacist.47  California, a state known for progressive legislation, 
represents the new era of expanded prescribing authority.  In line with the 
modern trend, California’s statute attempts to advance the rights and duties 
of pharmacists.48  However, the statute recognizes that detailed parameters 
and legislation must surround pharmacist prescribing if it is to become the 
norm.49 
III. ANALYSIS OF STATUTES 
A. Washington 
Washington’s Administrative Code has allowed pharmacists to enter 
into CPAs, called Collaborative Drug Therapy Agreements (CDTAs), with 
physicians since 1980.50  Pharmacists may exercise prescriptive authority in 
accordance with written guidelines or protocols previously established and 
approved by an authorized prescriber.51  These protocols must include a 
statement of the types of diseases, drug categories involved, and the type of 
prescriptive activity (e.g., modification or initiation of drug therapy) 
authorized in each case.52  There is no statutory authority to limit the classes 
or categories of drugs that physicians may allow pharmacists to prescribe.53  
Under a CPA, a pharmacist can prescribe controlled substances with a Drug 
Enforcement Administration number, and the pharmacist is not limited to 
any specific setting (i.e. institutional).54  The protocol must include a 
statement of the activities that the pharmacist is to follow in the course of 
exercising prescriptive authority, including documentation of decisions 
made and a plan to provide feedback to the authorizing practitioner 
concerning specific decisions made.55  However, there is no statutorily 
required time frame for communication between the primary provider and 
 
 47   Id.; Gorman, supra note 11. 
 48   CAL. BUS. & PROF. CODE § 4016.5 (2018); see Gorman, supra note 11. 
 49   See Diana Yap, The Saga of SB 493: Hernandez and California’s New Provider Status 
Law, PHARMACY TODAY (Mar. 1, 2014), https://www.pharmacist.com/article/saga-sb-493-
hernandez-and-californias-new-provider-status-law. 
 50   See WASH. ADMIN. CODE § 246-863-100. 
 51   Id. at § 246-863-100(1). 
 52   Id. at § 246-863-100(2)(c)(i)(ii). 
 53   WASH. ADMIN. CODE § 246-863-100 (silent on limitations). 
 54   See DRUG ENFORCEMENT AGENCY, U.S. DEP’T OF JUSTICE, PRAC.’S MANUAL § 5 
(2006). 
 55   WASH. ADMIN. CODE § 246-863-100(2)(d). 
PLINIO (DO NOT DELETE) 4/10/2020  6:54 PM 
2020] YOUR PHARMACIST WILL SEE YOU NOW 405 
the pharmacist upon initiation of medication.56  Additionally, there is no 
language in the statute pertaining to additional training or residency 
requirements.57 
Currently, there are over 33,000 active CDTAs in the state of 
Washington.58  Though CDTAs have been abundant in the state since 1979, 
inquiries into their scope are more recent and compelling.59  In 2018, the 
Washington Medical Commission sought a formal opinion from the state 
Attorney General regarding the scope of pharmacists’ authority.60  The 
request sought, in part, to clarify whether a pharmacist’s duties under a 
CDTA included diagnosis.61  Additionally, the request inquired whether a 
physician could delegate diagnosis responsibilities to a pharmacist under a 
CDTA.62  Finally, the request asked if a pharmacist diagnosing a patient 
pursuant to a CDTA constitutes an unlicensed practice of medicine.63  The 
Commission took the position that the duty of a pharmacist does not include 
diagnosis, and therefore a physician cannot delegate this responsibility.64  
However, the response noted that the Commission does not acknowledge any 
statutes or rules that govern the responsibilities or limitations of physician 
delegation under a CDTA.65 
In response to this request, the National Alliance of State Pharmacy 
Associations (NASPA) and the National Community Pharmacist’s 
Association (NCPA) submitted a joint letter to the state Attorney General’s 
office.66  In the letter, NASPA and NCPA argued that Washington State 
pharmacists prescribing pursuant to a CDTA must do so in accordance with 
the terms agreed upon in the CDTA.67  If a prescriber includes diagnosing or 
independent prescribing activities in the guidelines or protocols of the 
CDTA, then pharmacists may do so per the terms of the agreement.68  
NASPA and NCPA also asserted that Chapter 18.64 of the Washington 
Administrative Code (WAC) governs the practice of pharmacy and it cannot 
 
 56   WASH. ADMIN. CODE § 246-863-100 (silent on communication time frame). 
 57   WASH. ADMIN. CODE § 246-863-100 (silent on additional training or education). 
 58   Letter from the Nat’l All. of State Pharmacy Ass’ns. & Nat’l Cmty. Pharmacists 
Ass’n. to Jeff Even, Deputy Solic. Gen. (Aug. 9, 2018) (on file with author). 
 59   Id. at 2–3. 
 60   Letter from the Wash. Med. Comm’n to Bob Ferguson, Attorney Gen. 10 (Jun. 8, 
2018) (on file with author). 
 61   Id. at 5. 
 62   Id.  
 63   Id.  
 64   Id.  
 65   Id. at 10. 
 66   See Letter from the Nat’l All. of State Pharmacy Ass’ns. & Nat’l Cmty. Pharmacists 
Ass’n. to Jeff Even, Deputy Solic. Gen. 1 (Aug. 9, 2018) (on file with author). 
 67   Id. at 4. 
 68   Id. at 5. 
PLINIO (DO NOT DELETE) 4/10/2020  6:54 PM 
406 SETON HALL LEGISLATIVE JOURNAL [Vol. 44:2 
impose any limitations on non-pharmacists—including duties non-
pharmacist prescribers are authorized to delegate to pharmacists.69  NASPA 
and NCPA contended that pharmacists are limited in their scope of authority 
by threat of litigation and ethical duty alone.70  The letter states that 
“Pharmacists have an ethical duty to self-restrain from accepting any 
delegation of patient care services beyond their individual competency.”71  
The letter points out that since the establishment of the CDTA in 
Washington, there have been no lawsuits questioning CDTA’s legal 
authority or asserting patient harm caused by their use.72  As a result, the two 
groups contend that there is no need for further regulatory restriction on the 
use of CDTAs.73 
The conflicting opinions between the Washington Medical 
Commission, NASPA, and NCPA are further evidence of the need for state 
restriction on the practice of pharmacy.  The Washington Medical 
Commission recognizes the vagueness of the statutes governing 
pharmacists’ scope of practice.74  The Commission seeks to clarify the 
overbroad statutory language that leaves patients at risk of receiving subpar 
care.  The NASPA and NCPA wrongfully rely on the lack of lawsuits as 
evidence that the current system is working.75  However, as the patient 
population and patient needs increase, physicians will be forced to look to 
secondary providers to ease their burdens.76  The State must protect 
pharmacists from broad delegations of duty that cannot be adequately 
discharged.  Further, allowing the pharmacy profession to regulate itself on 
ethics alone is irresponsible.  Such a regulatory scheme will pressure 
pharmacists to accept more responsibility than qualifications can justify so 
the needs of their supervising physicians are satisfied.  Pharmacists will be 
caught in an ethical conundrum between whether to help patients who need 
care, or to acknowledge certain limitations and reject a physician’s delegated 
duties. 
 
 69   Id.  
 70   Id. at 6. 
 71   Id. at 6. 
 72   Letter from the Nat’l All. of State Pharmacy Ass’ns. & Nat’l Cmty. Pharmacists 
Ass’n. to Jeff Even, Deputy Solic. Gen. 3 (Aug. 9, 2018) (on file with author). 
 73   Id.  
 74   See Letter from the Wash. Med. Comm’n, supra note 60, at 3. 
 75   See Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 76   Gorman, supra note 11 (“[H]ealth officials are looking for ways to ease the strain on 
overloaded doctors, improve care and contain costs. With millions of people gaining coverage 
under the nation’s health law, experts say pharmacists can fill gaps in primary care and help 
avoid unnecessary hospital admissions.”). 
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B. California 
Before the introduction of the Advanced Practice Pharmacist license, 
California pharmacists could only prescribe in accordance with a CPA 
alongside a physician in an institutional setting.77  Institutional settings 
include hospitals, nursing homes, and long-term care facilities—places 
where interaction between all members of a patient’s health care team are 
frequent.78  A pharmacist was required to complete clinical residency 
training, or demonstrate clinical experience in direct patient care delivery, 
prior to entering into a CPA.79  In 2014, California introduced the Advanced 
Practice Pharmacist license.80  President of the California Chapter of the 
American College of Emergency Physicians, Tom Sugarman, M.D., stated 
that “[t]o ensure patient safety and quality of care, it’s critical to have the 
physician as the point of contact for care.”81  Sugarman also noted his 
particular concerns about the license’s creation of a new pharmacist class of 
opioid prescribers in a time where over prescribing of such drugs is already 
a highly volatile issue.82 
C. Comparison 
Because California’s Advanced Practice Pharmacist initiative faced 
such opposition when it was first introduced, it was consequently amended 
several times to ensure that it was limited and specific in its prescriptive 
authority.83  These amendments ensured that while pharmacists could still 
benefit from an expansion in their prescriptive authority, they could only do 
so with specific and explicit limitations.84  California community 
pharmacists seeking to enter into CPAs as Advanced Practice Pharmacists 
are required to complete extra training on patient care and drug therapy 
management.85  The law also requires communication between the 
 
 77   CAL. BUS. & PROF. CODE § 4052.2(a). 
 78   See id. 
 79   CAL. BUS. & PROF. CODE § 4052.2(d). 
 80   CAL. BUS. & PROF. CODE § 4016.5 (2018). 
 81   Grimes, supra note 11. 
 82   Grimes, supra note 11. 
 83   Yap, supra note 49. 
 84   See Yap, supra note 49. 
 85   CAL. BUS. & PROF. CODE § 4210 (2018). This further training requires the pharmacist 
to satisfy two out of three of the following criteria: (1) earn certification in a relevant area of 
practice, including, but not limited to, ambulatory care, critical care, geriatric pharmacy, 
nuclear pharmacy, nutrition support pharmacy, oncology pharmacy, pediatric pharmacy, 
pharmacotherapy, or psychiatric pharmacy, from an organization recognized by the 
Accreditation Council for Pharmacy Education or another entity recognized by the board; (2) 
complete a postgraduate residency through an accredited postgraduate institution where at 
least 50 percent of the experience includes the provision of direct patient care services with 
interdisciplinary teams; (3) have provided clinical services to patients for at least one year 
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pharmacist and physician within 24 hours of initiating new medication.86  
This is especially important in a community pharmacy setting, such as a 
Walgreens or Rite Aid, where interactions with the primary physician and 
pharmacist may be less frequent.  Additionally, all CPAs require approval 
from the state’s pharmacy board.87 
Washington State’s Administrative Code allows for much broader 
pharmacist authority and relies greatly on deference to the physician and 
pharmacist.88  Though the Washington Medical Commission argues that the 
law should not allow a pharmacist to prescribe, this is not clear from the 
statute.89  NASPA and NCPA argue that the law allows for total delegation 
by a physician of prescribing and diagnosing authority to a pharmacist in any 
setting, if desired.90  Regardless of the true meaning behind the statute, it is 
clear that further regulation and clarification are needed.91 
The only requirement for specificity of the CDTA is a mandatory list 
of the types of diseases, drugs, or drug categories covered by the agreement.92  
This leaves much of the decision making up to the pharmacists if they choose 
not to consult with their supervising physicians prior to writing a 
prescription.  The law includes no discussion of limitation in setting, granting 
community pharmacists the same level of authority as institutional setting 
pharmacists without any additional training or communication requirement.  
Furthermore, there is no requirement for additional training for a pharmacist 
seeking to enter into a CDTA, regardless of setting. 
In regards to communication, the law states that the CDTA must 
include “a plan for communication or feedback to the authorizing 
practitioner concerning specific decisions made,” but does not include a time 
frame for the pharmacist to report diagnoses or initiation of new medications 
to the physician.93  Frequency of communication is left up to the pharmacist 
and physician, which could result in delayed communication after initiation 
of medication leading to patient harm.  Unlike California’s law, the 
 
under a collaborative practice agreement or protocol with a physician, advanced practice 
pharmacist, pharmacist practicing collaborative drug therapy management, or health system.  
 86   CAL. BUS. & PROF. CODE § 4052. 
 87   CAL. BUS. & PROF. CODE § 4210. 
 88   See WASH. ADMIN. CODE § 246-863-100. 
 89   Letter from the Washington Medical Comm’n, supra note 60. 
 90  Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 91  The Washington State Attorney General’s Office has yet to release a response to either 
party. 
 92  WASH. ADMIN. CODE § 246-863-100(2)(c)(i)(ii). This is not an inclusive list. A 
physician may, but is not required to, include specific drugs or drug categories, such as 
amoxicillin, or antibiotics generally. If the physician chooses, he or she may authorize a 
pharmacist to prescribe for a disease state, such as high blood pressure or asthma, with no 
mention of drug classes or categories. 
 93  WASH. ADMIN. CODE § 246-863-100(2)(d). 
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Washington law, allowing pharmacist prescribing through a CDTA, has not 
been updated in recent years.94  As it stands, it seems the legislature is content 
to rely on feedback from the medical field to initiate changes to the CDTA 
law.95 
IV. IMPLICATIONS OF EXPANDED AUTHORITY 
A. Benefits of Expansion 
Though some argue that pharmacists and other second level health care 
providers should not have the right to prescribe, with the proper legislative 
guidance, pharmacists can exercise their limited prescriptive authority safely 
and effectively to the great benefit of the medical community.96  One of the 
driving factors behind expanding prescribing rights has always been the need 
to serve the growing patient population.97  Physicians alone cannot keep up 
with the masses of patients who need medical care, and other groups of 
health care providers can alleviate this burden.98  In medically underserved 
populations, it may be too expensive or burdensome for patients to visit a 
physician every time they need a prescription.99  Examples of these 
underserved populations include both poor rural and inner-city Americans, 
as well as the elderly.100  These populations might see their doctor once a 
year but may see their community pharmacist weekly, allowing them to form 
a close relationship with their local pharmacist.  Due to the ease of access, 
they may be more comfortable asking questions and more likely to make an 
in-person visit in case of a problem.101 
Additionally, many pharmacists believe they are practicing below their 
degrees.102 Pharmacists practicing in retail drug stores spend the majority of 
their time on activities that do not require a pharmacist license.103  A survey 
 
 94  WASH. ADMIN. CODE § 246-863-100. 
 95  See WSMA Weighs in as State Attorney General Considers Pharmacists’ Scope of 
Practice, WASH. STATE MED. ASS’N, (Aug. 8, 2018), 
https://wsma.org/Shared_Content/News/Membership_Memo/20180808/wsma_weighs_in_a
s_state_attorney_general_considers_pharmacists_scope_of_practice. Without the inquiry by 
Washington Medical Commission, it is unlikely that the Attorney General would have 
addressed the issue raised. As of this article, the Attorney General has yet to issue an opinion 
on the matter. 
 96   See, e.g., Coleman, supra note 1, at 67. 
 97   Gorman, supra note 11. 
 98   See Gorman, supra note 11. 
 99   See Coleman, supra note 1, at 55-58. 
 100   Coleman, supra note 1, at 55-58. 
 101   See Gorman, supra note 11. 
 102   See Jannet M. Carmichael & Janice A. Cichowlas, The Changing Role of Pharmacy 
Practice - A Clinical Perspective, 10 ANN. HEALTH L. 179, 186 (2001). 
 103   Id. at 185. 
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conducted by the National Association of Chain Drug Stores Education 
Foundation showed that pharmacists were spending sixty-eight percent of 
their time on processing orders and prescriptions, managing inventory, and 
other miscellaneous activities that do not require a licensed pharmacist.104  
The survey determined that pharmacists were spending only thirty-one 
percent of their time on activities that actually require a licensed pharmacist, 
including reviewing and interpreting prescriptions, assessing patients’ drug 
therapy, and counseling patients.105 
Although they may not attend medical school, pharmacists receive 
highly technical training in drug therapy management.106  Pharm.D. 
programs usually include four years of professional study, followed by two 
to four years of preprofessional education.107  In their six to eight years of 
study, Pharm.D. students take courses in biology, chemistry, pharmacology, 
pharmacotherapy, patient assessment, and medical ethics.108  The students 
also receive experience-based education to gain experience providing care 
to patients through services such as immunizations, medication 
management, chronic disease management, patient assessment, and many 
others.109  Though pharmacists may not receive training specifically on 
diagnosis and medication selection, by working with a physician, 
pharmacists are more than capable of making decisions regarding patient 
care and prescribing. 
B. Hazards of Expansion 
Many of the potential issues with pharmacist prescribing come from a 
lack of communication between physician and pharmacist.110  It is unclear 
how involved a physician needs to be in a CPA, as there are not always 
specific requirements for meaningful communication and collaboration 
beyond a notification when a pharmacist initiates a medication.111  This lack 
of specificity creates a high risk of miscommunication or lack of 
communication, especially in a community pharmacy where a pharmacist is 
not working alongside a physician in the same hospital as nurses and 
 
 104   Id.  
 105   Id.  
 106   See Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 107   Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 108   Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 109   Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 110   See Keri D. Hager, Donald Uden & Daniel M. Tomaszewski, Bridging the Location 
Gap: Physician Perspectives of Physician-Pharmacist Collaboration in Patient Care 
(BRIDGE Phase II), 5.2 J. OF RES. IN INTERPROFESSIONAL PRAC. AND EDUC. 1 (2015). 
 111   See, e.g., WASH. ADMIN. CODE § 246-863-100 (silent on further communication 
requirements). 
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physician’s assistants typically do.112  Even for higher level secondary 
prescribers, such as nurse practitioners, lack of communication is still a 
pertinent issue that becomes more troublesome as prescribing rights are 
expanded to more groups.113  In Collip v. Ratts, a physician entered into a 
CPA with a nurse practitioner.114  The CPA required the physician to review 
at least five percent of the nurse’s charts on a weekly basis and to document 
her prescribing practices.115  The physician had entered into eleven other 
CPAs and also maintained a ninety-hour-per-week medical practice; he 
admitted that he only engaged in a limited review of the nurse’s notes.116  He 
became concerned about the amount of narcotics that the nurse was 
prescribing to her patients but never followed up.117  Ultimately, one of the 
nurse’s patients, who had never been treated, seen, or heard of by the 
physician, died as a result of multiple drug interactions.118  This tragedy 
occurred in a situation where the nurse and physician were working in close 
proximity – a practice that is much less common in a pharmacist-physician 
relationship.119  Even more concerning is that nurse practitioners, despite the 
advanced training they are required to have in order to prescribe, are still at 
risk to make catastrophic mistakes without sufficient physician 
supervision.120  Pharmacists are subject to this same risk, but without the 
requirement of advanced training or sufficient physician communication.121 
Pharmacists should be allowed to utilize some form of prescriptive 
power.  The current legislative landscape, however, leaves too much room 
for over-delegation by the physician and too much discretion to the 
pharmacist. As previously stated, pharmacists are not trained in diagnosis.122  
The NASPA and NCPA are comfortable with a pharmacist in Washington 
making a diagnosis and subsequently prescribing a medication if this is what 
the physician has delegated under a CDTA.123  This is troubling, especially 
in light of the fact that a pharmacist in that state is not required to receive 
extra training in diagnosis, prescribing, or patient care in order to enter into 
 
 112   See Collip v. Ratts, 49 N.E.3d 607 (Ind. Ct. App. 2015). 
 113   See id. 
 114   Id. at 609. 
 115   Id.  
 116   Id. at 610. 
 117   Id. 
 118   Collip v. Ratts, 49 N.E.3d 607, 611 (Ind. Ct. App. 2015). 
 119   Compare Collip, 49 N.E.3d at 607, with Hager, supra note 110 at 2. 
 120   Coleman, supra note, at 60; see Collip, 49 N.E.3d at 611. 
 121   See, e.g., WASH. ADMIN. CODE § 246-863-100 (no mention of extra training or 
communication requirements). 
 122   Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 123   Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
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a CDTA.124  The only limitation to the pharmacist’s authority is the 
physician’s discretion in delegating and the pharmacist’s ethical code.125  
This is a recipe for overprescribing and mis-prescribing of medication.  
Extending prescribing rights to any secondary health care provider carries 
these same risks.126 
In  Evans v. Griswold, an optometrist prescribed an antibiotic for a 
patient that he diagnosed as suffering from a bacterial eye infection.127  The 
patient’s condition did not improve, and the optometrist sent her for tests and 
stopped treatment.128  The patient returned almost two weeks later because 
her eye was worse, and the optometrist recommended she take the same 
antibiotic for another ten days.129  Two days later, the patient consulted an 
ophthalmologist who concluded that the patient was experiencing a toxic 
reaction to the medication that had not been recognized by the optometrist.130 
Similar to pharmacists, optometrists receive an advanced degree and 
are able to prescribe some medication in a limited capacity but are not 
considered medical doctors.131  An ophthalmologist is a medical doctor who 
has completed college and at least eight years of additional medical training 
and is licensed to practice medicine and surgery.132  It is not difficult to see 
how a similar situation could easily arise between a pharmacist prescribing 
for a simple infection in accordance with a CPA, only to find that the patient 
experiences an unforeseen reaction.  Even ordinarily benign drugs like 
antibiotics or hormonal birth control have side effects which may affect 
individuals in unusual ways.133  Pharmacists may not always have sufficient 
knowledge to respond to these unexpected problems arising from their 
prescriptions.134 
A similar example is pharmacist-prescribed hormonal birth control.  
Hormonal birth control is generally seen as innocuous, and many believe it 
could someday be granted over-the-counter status by the FDA.135  Oregon 
 
 124   WASH. ADMIN. CODE § 246-863-100 (no mention of extra training or education). 
 125   Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 126   See Evans v. Griswold, 935 P.2d 165 (Idaho 1997); Collip, 49 N.E.3d at 607. 
 127   Evans, 935 P.2d at 166. 
 128   Id. at 166-67. 
 129   Id. at 167. 
 130   Id. 
 131   Difference Between an Ophthalmologist, Optometrist and Optician, AMERICAN 
ASS’N. FOR PEDIATRIC OPHTHALMOLOGY AND STRABISMUS, 
https://aapos.org/glossary/difference-between-an-ophthalmologist-optometrist-and-optician 
(last visited Jan. 17, 2020). 
 132   Id. 
 133   See, e.g., Evans, 935 P.2d at 165. 
 134   See Coleman, supra note, at 57-58. 
 135   Maria I. Rodriguez, K. John McConnell, Jonas Swartz & Alison B. Edelman, 
Pharmacist Prescription of Hormonal Contraception in Oregon: Baseline Knowledge and 
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and California have both passed laws allowing pharmacists to prescribe short 
acting hormonal contraception to women without a visit to a physician.136  
The pharmacist must first complete a five hour training module covering 
information on contraception mechanisms of action and patient counseling 
on issues such as pill adherence, side effects, and potential interactions.137  
However, a statewide survey conducted in Oregon revealed that only thirty-
nine percent of pharmacists were interested in prescribing birth control.138  
Most of the pharmacists in this minority group cited the need for further 
training in general contraception information and identifying 
contraindications before they would feel comfortable independently 
prescribing.139  It seems that even a number of pharmacists are uncomfortable 
with the level of authority they have been given by the legislature.140 
Not all drugs in the same class or category are created equal, and not 
all diseases can be treated by just one type of drug.  A disease state or drug 
class listed in a CPA may not give pharmacists enough direction on what to 
prescribe, with the differences leading to small but potentially significant 
effects for the patient.141  Additionally, granting pharmacists this discretion 
will allow them to make choices between brands of drugs, which will 
introduce them to the issues facing physician prescribers and pharmaceutical 
companies.  Pharmaceutical companies may decide to target their marketing 
to pharmacists, who do not receive training on transparency and anti-
kickback laws.  As it stands, the Sunshine Act only requires that 
pharmaceutical companies report their spending on primary health care 
providers.142  Companies are not required to report spending on secondary 
health care providers, including pharmacists, even if those pharmacists are 
prescribers.143  This exemption creates a huge loophole that could be used by 
 
Interest in Provision, 56.5 J. AM. PHARMACISTS ASS’N 521, 522 (2016). 
 136   Id. at 521. 
 137   Id. at 522. 
 138   Id. at 524. 
 139   Id. 
 140   See id. 
 141   Patricia A. Marken & J. Stuart Munro, Selecting a Selective Serotonin Reuptake 
Inhibitor: Clinically Important Distinguishing Features, 2 PRIMARY CARE COMPANION J. 
CLINICAL PSYCHIATRY 205 (Dec. 2000). 
For example, a physician may authorize a pharmacist to prescribe a selective serotonin 
reuptake inhibitor (SSRI) to a patient with a diagnosis of depression. All SSRIs have the same 
mechanism of action and are similarly efficacious for the treatment of depression. However, 
individual patients may respond differently to the same SSRIs, and.individual pharmacologic 
differences may make one SSRI more or less suited for a given patient.  
 142   42 CFR § 403.902. The Sunshine Act requires that manufacturers of drugs and 
medical devices that are reimbursable by federal health care programs to track and report to 
the Centers for Medicare and Medicaid Services (CMS) all financial relationships with 
physicians. The law aims to increase transparency and uncover potential conflicts of interest.  
 143   Id.; Thomas Sullivan, Physician Payment Sunshine Act Final Rule: Definitions, POL’Y 
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pharmaceutical companies to avoid the system put in place to discourage 
bribery of heath care providers. 
This loophole is particularly significant in the context of the opioid 
epidemic.  There is great danger in introducing a new class of opioid 
prescribers in a market already rampant with overprescribing.144  The 
Department of Justice has increased scrutiny on offenders from every level 
of the system in the opioid-saturated market.145  Physicians, pharmaceutical 
companies and their representatives, and even pharmacists have been 
targeted by lawsuits from both private citizens and the government.146  A 
pharmacist able to prescribe opioids pursuant to a CPA or CDTA is now a 
new target for opioid users, abusers, and eventually prosecutors.  Opioid 
users may use these new pharmacist prescribers to skip the trip to the 
physician, leaving one less barrier to the addictive drugs. 
There is also a question of liability and standard of care in expanding 
prescribing rights.  If a pharmacist makes a mistake while acting in 
accordance with a CPA, the law is not always clear on whether it is the 
pharmacist or the physician who will be held liable.147  The Court of Appeals 
of Indiana addressed this issue in a case concerning a CPA between a nurse 
practitioner and a physician.148 The court stated, “[i]f a doctor complied with 
his or her review and oversight obligations . . . and sees nothing troubling, 
and one of the patients is harmed by the negligence of the nurse practitioner, 
the doctor has not breached the duty to that patient.”149  This suggests that so 
long as the physician complies with the CPA he or she drafted, the physician 
will not be liable.150  The liability will instead fall to the secondary health 
care provider.151 
 
 
 
There are differing opinions as to the standard of care that is expected 
 
& MED. (May 6, 2018), https://www.policymed.com/2013/02/physician-payment-sunshine-
act-final-rule-definitions.html. 
 144   Grimes, supra note 11. 
 145   See Nate Raymond & Jonathan Stempel, U.S. Joins Whistleblower Case Against Insys 
Over Kickbacks, REUTERS (May 14, 2018), https://www.reuters.com/article/us-insys-
opioids/u-s-joins-whistleblower-case-against-insys-over-kickbacks-idUSKCN1IF31M. 
 146   See David Armstrong, Lawsuit Blames Improper Marketing of Potent Opioid for 
Woman’s Death, STAT NEWS (Mar. 24, 2017), 
https://www.statnews.com/2017/03/24/opioid-insys-improper-marketing-lawsuit/; 
Raymond, supra note 145. 
 147   See Collip, 49 N.E.3d at 607. 
 148   Id. at 609. 
 149   Id. at 615. 
 150   See Collip, 49 N.E.3d at 615. 
 151   See id. 
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from a prescribing pharmacist.152  Currently, two different standards are 
applied to secondary health care providers performing tasks traditionally 
reserved to medical doctors, such as prescribing.153  Under the first and more 
stringent standard, prescribing pharmacists are considered to be acting as 
doctors, and are held to that same high standard of care.154  Courts generally 
shy away from applying this higher standard to secondary providers.155  The 
second lower standard provides that because of their limited education, 
secondary providers should be held to the standard of care of a “reasonably 
prudent professional of similar experience and training.”156  The standard 
asks whether the health care provider exercised the specific knowledge and 
skill of similar professionals.157  This allows each profession to set its own 
standards on how it will be judged.158  However, if secondary health care 
providers believe they are able to prescribe just as well as physicians without 
sacrificing patient safety, their argument against holding them to a 
physician’s standard of care is illogical.159  This “similar professional” rule 
lowers the bar for prescription errors and other functions traditionally within 
the exclusive domain of a physician.160 
C. Suggestions for Legislative Reform 
It is clear that this area of the law needs further regulation and 
clarification.  It is not sufficient that the legislature defers to the medical 
community to initiate change.  The medical community is not able to agree 
on the best path for pharmacist prescribing, or if it should even exist at all.  
With so much discord between physicians and secondary prescribers, the 
legislature needs to act as a neutral third party to determine what is truly in 
the best interest of the people.  Collaboration between different healthcare 
providers can reduce healthcare costs and improve patient outcomes.161  
However, pharmacists in community settings find this collaboration to be 
 
 152   See Coleman, supra note, at 78. 
 153   See Coleman, supra note 1, at 72. 
 154   See Coleman, supra note 1, at 72. 
 155   See Coleman, supra note 1, at 73. 
 156   See Coleman, supra note 1, at 72. 
 157   Coleman, supra note 1, at 75; see, e.g., N.C. GEN. STAT. § 90-21.12 (2018) (stating 
that, in determining damages for malpractice, the trier of facts must consider whether the care 
was “in accordance with the standards of practice among members of the same health care 
profession with similar training and experience . . .”); IDAHO CODE § 6-1012 (2018) 
(“individual providers of health care shall be judged in such cases in comparison with 
similarly trained and qualified providers of the same class in the same community, taking into 
account his or her training, experience, and fields of medical specialization, if any.”). 
 158   Coleman, supra note, at 75-76. 
 159   Coleman, supra note 1,  at 78-79. 
 160   Coleman, supra note 1, at 78. 
 161   Hager, supra note 110, at 2. 
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particularly challenging as they have great difficulty communicating with 
the delegating physician.162  Some physicians report a lack of trust between 
themselves and community pharmacists as compared to institutional 
pharmacists.163  Other physicians report that their limited communications 
with pharmacists outside their own practice are impersonal and often 
unclear.164  This lack of trust and clarity can be combatted by frequent, 
meaningful, and mandatory communications between physicians and 
pharmacists entering into a CPA. 
There must be a guarantee that pharmacists and physicians will 
communicate about the patients being treated.  It seems many physicians and 
pharmacists want this level of effective communication, but simply need 
assistance from the legislature or state boards in order to achieve it.165  At the 
very least, state pharmacy boards should implement communication 
requirements for CPAs.  In addition, state legislators could set statewide 
minimum standards for communication between physicians and pharmacists 
entering a CPA.  This will ensure actual collaboration between the physician 
and pharmacists, as the legislature intended, and not just pharmacists 
prescribing independently under the “oversight” of an absentee physician. 
There also should be limitations, either implemented by state boards of 
pharmacy or statute, on the types of medications pharmacists may prescribe.  
Any substance with a high potential for abuse, including opioids and other 
Schedule II controlled substances, should be excluded from a pharmacist’s 
prescriptive authority.166  These drugs can cause severe psychological or 
physical dependence, especially when over or mis-prescribed.167  Therefore, 
patients should be required to visit a physician to obtain a prescription.  At 
the very least, if the state is not comfortable creating a banned drugs list, the 
legislature should require that a CPA list the specific drugs a pharmacist can 
prescribe for a specific diagnosis.  The pharmacist should not have the 
discretion to choose between different drugs in the same class or category.  
If the pharmacist wishes to make a change or is unsure of a diagnosis, he or 
she should be required to either contact the physician prior to making a 
change or refer the patient back to the physician.  Additionally, a pharmacist 
should not have the authority to diagnose a patient simply because a 
physician has delegated said authority.  In order to create any truly effective 
regulations surrounding pharmacist prescribing, clarification to the law 
 
 162   Hager, supra note 110, at 2. 
 163   Hager, supra note 110, at 4, 9. 
 164   See Hager, supra note 110, at 4, 7. 
 165   See Hager, supra note 110, at 4, 7. 
 166   For a list of such controlled substances, see Controlled Substance Schedules, DRUG 
ENFORCEMENT ADMIN., https://www.deadiversion.usdoj.gov/schedules/ (last visited Jan. 14, 
2019). 
 167  Id. 
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regarding physician delegation under a CDTA is required.  Specifically, the 
ability to diagnose patients should be unassignable to a pharmacist and 
should remain solely with the supervising physician. 
Finally, further training should be required for pharmacists seeking 
prescribing rights under a CPA.  Unlike nurses and physician’s assistants, 
pharmacists do not receive training in patient assessment and diagnoses in 
their education.  A short, one-day training course or an entirely online course 
are both insufficient methods in preparing a pharmacist for prescribing 
medication. If pharmacists wish to prescribe under a CPA, they should be 
required to undergo an extensive and meaningful training program. 
California’s Advanced Practice Pharmacist license, which requires extensive 
training in patient care and clinical services, can serve as a model to other 
states looking to expand prescribing rights.168 
V. CONCLUSION 
Pharmacists are on the front lines of patient care and are positioned to 
effectively prescribe medications if regulated properly.  Most states, 
including Washington and California, are on board with granting this group 
of providers broader authority to implement patient care regimens.169  These 
states recognize the potential pharmacists have to increase patient 
satisfaction and promote positive health outcomes.170 
Washington was one of the first states to allow for pharmacist 
prescribing under a CDTA, and the practice has become immensely popular 
throughout the state.171  California recently introduced a new advanced 
pharmacist license that allows for pharmacist prescribing under a CPA so 
long as the pharmacist meets the heightened license requirements.172  
However, granting pharmacists broad and undefined prescriptive authority 
could result in disaster.  The profession cannot be allowed to regulate itself 
entirely.  With physicians busier than ever, it is too easy for communication 
to fall to the wayside and for pharmacists to be saddled with more than they 
are qualified to accomplish.  The state legislature must regulate prescriptive 
authority to ensure adequate communication about patients and initiation of 
medication.  The state must also ensure that physician delegation is limited 
to correspond with a pharmacist’s training and education level.  Physicians 
should be prevented from assigning diagnosing duties to a pharmacist, and 
pharmacists should be prevented from accepting such duties.  Additionally, 
all Collaborative Practice Agreements need to have specific requirements, 
 
 168   See CAL. BUS. & PROF. CODE § 4052.6. 
 169   See CENTERS FOR DISEASE CONTROL AND PREVENTION, supra note 3, at 28–33. 
 170   See CENTERS FOR DISEASE CONTROL AND PREVENTION, supra note 3, at 3. 
 171   Letter from the Nat’l All. of State Pharmacy Ass’ns., supra note 58. 
 172   CAL. BUS. & PROF. CODE § 4052.6. 
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set by the state legislature, limiting the discretion of the pharmacist to an 
appropriate level.  Pharmacists seeking prescribing rights in any regard 
should be required by the state to undergo further advanced training in 
patient interaction, diagnosis, and prescribing in order to reduce the risk of 
patient harm.  Without these changes, problems of overprescribing and mis-
prescribing will continue to rise, pharmacists will hesitate to utilize their 
prescriptive power, and underserved populations will continue to suffer from 
a lack of care. 
 
